Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 12/20 | 0.51 |
| ▸ | TMPRSS4 | Q9NRS4 | 6/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.51 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.50 |
| ▸ | KCNMA1 | Q12791 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MYLK | Q15746 | 1/20 | 0.45 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665039 | 0.91 | PARK7 (0.50) | P2RX1TMPRSS4P2RX4P2RX7PARK7 | |
| SCHEMBL665474 | 0.88 | PARK7 (0.49) | P2RX1TMPRSS4P2RX4P2RX7PARK7 | |
| SCHEMBL666669 | 0.88 | PARK7 (0.53) | P2RX1TMPRSS4P2RX4P2RX7PARK7 | |
| SCHEMBL167099 | 0.86 | PARK7 (0.50) | P2RX1TMPRSS4PARK7MEN1KMT2A | |
| SCHEMBL666050 | 0.86 | PARK7 (0.50) | P2RX1TMPRSS4PARK7KCNMA1MEN1 | |
| Dehydroxymethylepoxyquinomicin SCHEMBL1669417 | 0.84 | PARK7 (0.54) | P2RX1P2RX4P2RX7PARK7KCNMA1 | |
| Dehydroxymethylepoxyquinomicin SCHEMBL14491796 | 0.84 | PARK7 (0.54) | P2RX1P2RX4P2RX7PARK7KCNMA1 | |
| Dehydroxymethylepoxyquinomicin SCHEMBL14504317 | 0.84 | PARK7 (0.54) | P2RX1P2RX4P2RX7PARK7KCNMA1 | |
| Dehydroxymethylepoxyquinomicin SCHEMBL1671089 | 0.84 | PARK7 (0.54) | P2RX1P2RX4P2RX7PARK7KCNMA1 | |
| SCHEMBL666087 | 0.82 | PARK7 (0.64) | PARK7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-02-23 | — | — | US | claimed |
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | NFKBIA, IKBKB, NFKB1 | P2RX1 855/4885TMPRSS4 2798/4885P2RX4 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.